CN102083413B - 用于治疗高眼压和青光眼的方法和组合物 - Google Patents
用于治疗高眼压和青光眼的方法和组合物 Download PDFInfo
- Publication number
- CN102083413B CN102083413B CN2009801197245A CN200980119724A CN102083413B CN 102083413 B CN102083413 B CN 102083413B CN 2009801197245 A CN2009801197245 A CN 2009801197245A CN 200980119724 A CN200980119724 A CN 200980119724A CN 102083413 B CN102083413 B CN 102083413B
- Authority
- CN
- China
- Prior art keywords
- aqueous solution
- antiseptic
- polyethylene
- container
- eye drip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 15
- 208000010412 Glaucoma Diseases 0.000 title abstract description 6
- 206010030043 Ocular hypertension Diseases 0.000 title abstract 3
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 14
- -1 polyethylene Polymers 0.000 claims description 101
- 230000002421 anti-septic effect Effects 0.000 claims description 66
- 239000004698 Polyethylene Substances 0.000 claims description 56
- 229920000573 polyethylene Polymers 0.000 claims description 56
- 239000007864 aqueous solution Substances 0.000 claims description 54
- 239000004094 surface-active agent Substances 0.000 claims description 34
- 229940054534 ophthalmic solution Drugs 0.000 claims description 27
- 239000002997 ophthalmic solution Substances 0.000 claims description 27
- 229960004458 tafluprost Drugs 0.000 claims description 27
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 27
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 22
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 20
- 239000003381 stabilizer Substances 0.000 claims description 20
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 17
- 239000012611 container material Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 230000004410 intraocular pressure Effects 0.000 claims description 12
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 10
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 10
- 229920001451 polypropylene glycol Polymers 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 229960002470 bimatoprost Drugs 0.000 claims description 8
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 8
- 229960001160 latanoprost Drugs 0.000 claims description 8
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 8
- 229960002368 travoprost Drugs 0.000 claims description 8
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims description 6
- 239000012929 tonicity agent Substances 0.000 claims description 6
- 229950008081 unoprostone isopropyl Drugs 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 claims description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 229920002292 Nylon 6 Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 claims description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004261 Ascorbyl stearate Substances 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002415 Pluronic P-123 Polymers 0.000 claims description 2
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 2
- 229920002642 Polysorbate 65 Polymers 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940059574 pentaerithrityl Drugs 0.000 claims description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229920001992 poloxamer 407 Polymers 0.000 claims description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 claims description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 claims description 2
- 229940101027 polysorbate 40 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940099511 polysorbate 65 Drugs 0.000 claims description 2
- IFIDXBCRSWOUSB-UHFFFAOYSA-N potassium;1,3-dichloro-1,3,5-triazinane-2,4,6-trione Chemical compound [K+].ClN1C(=O)NC(=O)N(Cl)C1=O IFIDXBCRSWOUSB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 235000010352 sodium erythorbate Nutrition 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 235000010288 sodium nitrite Nutrition 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- 229940046307 sodium thioglycolate Drugs 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 2
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 2
- 239000001589 sorbitan tristearate Substances 0.000 claims description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 claims description 2
- 229960004129 sorbitan tristearate Drugs 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 description 15
- 229960000686 benzalkonium chloride Drugs 0.000 description 11
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 229920001684 low density polyethylene Polymers 0.000 description 7
- 239000004702 low-density polyethylene Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229940018146 tafluprost ophthalmic solution Drugs 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000001742 aqueous humor Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- KIQXRQVVYTYYAZ-VKVYFNERSA-N (z)-7-[(1r,2r,3r,5s)-2-[(e)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 KIQXRQVVYTYYAZ-VKVYFNERSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000071 blow moulding Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000010102 injection blow moulding Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001179 medium density polyethylene Polymers 0.000 description 2
- 239000004701 medium-density polyethylene Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- FPABVZYYTCHNMK-YNRDDPJXSA-N PGF2alpha isopropyl ester Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C FPABVZYYTCHNMK-YNRDDPJXSA-N 0.000 description 1
- KIQXRQVVYTYYAZ-MTNCBHNASA-N Tafluprost free acid Chemical compound OC(=O)CCC\C=C/CC1C(O)CC(O)C1\C=C\C(F)(F)COC1=CC=CC=C1 KIQXRQVVYTYYAZ-MTNCBHNASA-N 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Inorganic materials [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011342 resin composition Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及含有PGF2α类似物用于治疗高眼压和青光眼的眼用含水组合物,通过给予需要这种治疗的受试者所述的组合物治疗高眼压和青光眼的方法,以及增加含水组合物中PGF2α类似物的水溶性和稳定性的方法。
Description
技术领域
本发明涉及含有***素(以下称为PG) F2α类似物用于治疗高眼压和青光眼的不含防腐剂的眼用含水组合物,通过给予需要这种治疗的受试者所述的组合物治疗高眼压和青光眼的方法,以及增加含水组合物中PGF2α类似物的水溶性和改善其稳定性的方法。
背景技术
由于PGF2α类似物降低眼内压的作用和它们低的全身性副作用,PGF2α类似物已经被广泛用于治疗青光眼和高眼压。PGF2α类似物包括所有已知的PGF2α类似物,例如他氟前列素(tafluprost)、拉坦前列素(latanoprost)、异丙基乌诺前列酮(isopropyl unoprostone)、曲伏前列素(travoprost)、比马前列素(bimatoprost)以及US 5,886,035、US 5,807,892、US 6,096,783中所示的类似物。
他氟前列素是新一代氟化的PGF2α异丙酯类似物,其为有效的降眼压剂(EP 0 850 926)。
PGF2α类似物用于治疗青光眼的浓度是非常低的。例如,已经发现他氟前列素在眼用组合物中的有效浓度0.0005-0.005 (w/v),优选约0.0015%足以用于治疗高眼压和青光眼。然而作为亲脂性物质,PGF2α类似物例如他氟前列素容易被通常用于储存眼用溶液的树脂(塑料) 容器或瓶吸收,因此可能进一步降低眼用溶液中已经很低的药物浓度。
防腐剂
对细菌和真菌显示充分抗菌作用的防腐剂传统上已被用于眼用组合物中。除此之外,需要防腐剂是稳定的,并且优选通过与组分相互作用匀化和稳定组合物,例如通过将组分均匀地分散或溶解于载体或基质中 (参见EP 0 969 846、EP 1 916 002和EP 1 547 599)。如今在商业可获得的眼用溶液中最常用的防腐剂为苯扎氯铵(BAK) 和其他季铵盐。其他药学可接受的用于眼用溶液的防腐剂为例如硼酸-多元醇-氯化锌 (EP 1 115 406) 或氧化氯化合物 (EP 1 905 453)、葡萄糖酸氯己定、苄索氯铵、山梨酸、山梨酸钾、对羟基苯甲酸乙酯和对羟基苯甲酸丁酯。
然而,防腐剂还被认为是角结膜障碍的主要病因,并且为了安全起见,优选防腐剂例如苯扎氯铵(BAK)的浓度尽可能地低。还已经研发了不含防腐剂的眼用溶液。
另一方面,BAK有助于防止***素降解和抑制***素被树脂容器壁吸收。他氟前列素和其他PGF2α类似物被树脂容器壁吸收已经成为问题,尤其是使用聚乙烯制造的容器。由于其性质,例如足够的弹性、柔软性、良好的可制造性和使用者友好性,聚乙烯是优选的用于包装眼用组合物,尤其是单位剂量形式的眼用组合物的材料。
此外,PGF2α类似物被树脂容器壁吸收取决于容器壁的表面积。单位剂量制剂含有非常少量的眼用组合物,制剂与容器的接触面积非常大。因此,PGF2α类似物被容器壁吸收对于单位剂量制剂而言是严重的问题。
因此,在本发明之前实践中不可能制备稳定的、不含防腐剂的眼用溶液,所述溶液含有PGF2α类似物并且可以包装并储存于基本上由聚乙烯组成的容器中。根据EP 1011728,包装于聚丙烯容器中的含水***素组合物比包装于聚乙烯容器中的更稳定。基于所述出版物的稳定性结果,不鼓励技术人员选择聚乙烯,而且可能会禁止其作为容器材料,尤其是对于所有高亲脂性化合物例如PGF2α类似物。包含聚乙烯作为次要成分的聚丙烯-聚乙烯共聚物也是可能的,但并非暗示聚乙烯作为唯一的材料或作为主要的树脂组分 (EP 1 829 545)。
此外,几乎所有的PGF2α类似物是几乎不溶于水的。因此为了在眼用溶液尤其是单位剂量制剂中配制PGF2α类似物,还需要解决对水的溶解性问题。在EP 1 321 144和US 2007/248697中,已经将非离子表面活性剂添加到眼用溶液中以防止***素衍生物被树脂容器吸附。解决在水中配制高亲脂性***素类似物的难题的其他尝试描述于例如EP 0 969 846、EP 1 666 043、EP 1 011 728和WO 2007/042262中,但是它们没有提及任何不含防腐剂的组合物。
因此本发明的目的在于提供一种包含PGF2α类似物并且基本上不含防腐剂的眼用含水溶液,其中防止PGF2α类似物被基本上由聚乙烯组成的树脂容器吸收,并且其中所述的类似物在不含防腐剂的制剂中保持溶解、稳定以及可生物利用。由于目前青光眼患者对不含防腐剂的***素滴眼剂的临床需求未得到满足,因此根据本发明的眼用含水溶液提供显著的临床优势。
发明内容
本发明涉及包含PGF2α类似物作为其有效成分用于治疗高眼压和青光眼的眼用含水溶液,该溶液在基本上由聚乙烯组成的容器中含有非离子表面活性剂、稳定剂,并且基本上不含防腐剂。
本发明还涉及一种治疗高眼压和青光眼的方法,该方法包含给予需要所述治疗的受试者包含PGF2α类似物作为其有效成分的含水眼用溶液,其中该眼用溶液含有非离子表面活性剂、稳定剂,并且基本上不含防腐剂。
此外,本发明涉及PGF2α类似物在制备用于治疗高眼压和青光眼的眼用含水溶液中的用途,其中所述溶液含有非离子表面活性剂、稳定剂,基本上不含防腐剂并且储存在基本上由聚乙烯组成的容器中。
本发明的另一目的是增加眼用含水溶液中PGF2α类似物的水溶性和改善其稳定性的方法,包含制备含有PGF2α类似物、非离子表面活性剂、稳定剂并且基本上不含防腐剂的眼用含水溶液,以及将不含防腐剂的眼用溶液包装在基本上由聚乙烯组成的容器中的步骤。
在本说明书中,“基本上不含防腐剂”或“不含防腐剂”是指溶液完全不含有防腐剂,或者溶液含有检测不到的浓度的防腐剂或者不提供防腐效果。
附图说明
图 1-3显示在5℃、25℃和40℃下在三种不同的聚山梨酯浓度下聚山梨酯80 (吐温80; TW) 分别对不含防腐剂的他氟前列素被低密度的聚乙烯容器吸收的作用。
图4显示在单次滴注BAK-防腐的0.0015%他氟前列素的眼用溶液[BAK(+)],含有0.20%吐温80的非-防腐的0.0015%他氟前列素眼用溶液[BAK(-) 0.2%吐温80],或含有0.05%吐温80的非-防腐的0.0015%他氟前列素眼用溶液[BAK(-) 0.05%吐温80]后家兔房水中酸式他氟前列素的浓度。棒表示在每个时间点他氟前列素酸式浓度的平均值的标准误,星号表示BAK(-) 0.2%吐温80 和BAK(-) 0.05%吐温80 溶液之间他氟前列素酸式浓度的统计学显著性差异(p<0.05,N=8)。
具体实施方式
非离子表面活性剂由于其增溶作用而被添加到本发明的眼用溶液中并且用于防止PGF2α类似物被容器的树脂壁吸收。非离子表面活性剂的实例为聚氧乙烯脂肪酯,例如聚山梨酯80[聚(氧乙烯)脱水山梨糖醇单油酸酯]、聚山梨酯60[聚(氧乙烯)脱水山梨糖醇单硬脂酸酯]、聚山梨酯40[聚(氧乙烯)脱水山梨糖醇单棕榈酸酯]、聚(氧乙烯)脱水山梨糖醇单月桂酸酯、聚(氧乙烯)脱水山梨糖醇三油酸酯和聚山梨酯65[聚(氧乙烯)脱水山梨糖醇三硬脂酸酯],聚氧乙烯氢化蓖麻油类,例如聚氧乙烯氢化蓖麻油10、聚氧乙烯氢化蓖麻油40、聚氧乙烯氢化蓖麻油50和聚氧乙烯氢化蓖麻油60,聚氧乙烯聚氧丙烯二醇类,例如聚氧乙烯(160)聚氧丙烯(30)二醇[普朗尼克(Pluronic)F68]、聚氧乙烯(42)聚氧丙烯(67)二醇[普朗尼克P123]、聚氧乙烯(54)聚氧丙烯(39)二醇[普朗尼克P85]、聚氧乙烯(196)聚氧丙烯(67)二醇[普朗尼克F127]和聚氧乙烯(20)聚氧丙烯(20)二醇[普朗尼克L-44],聚乙二醇40硬脂酸酯和蔗糖脂肪酯。非离子表面活性剂可以单独或组合使用。优选的非离子表面活性剂的实例为聚山梨酯80[聚(氧乙烯)脱水山梨糖醇单油酸酯]。其他优选的非离子表面活性剂为聚氧乙烯氢化蓖麻油60和聚乙二醇40硬脂酸酯。
可以根据***素类似物的量和类型以及具体的表面活性剂选择本发明的眼用溶液中的非离子表面活性剂的量,并且在本领域技术人员的能力内。对于聚山梨酯80,其浓度为例如0.05-0.5%(w/v) 的范围内,甚至更优选0.05-0.1%,以及最优选约0.075%。本发明人还已发现过高浓度的非离子表面活性剂对角膜上皮层有刺激作用,对眼用溶液中***素的生物利用度有不利作用。例如在他氟前列素的情况中,非离子表面活性剂聚山梨酯80 0.5%的上限是合适的。
根据本发明的眼用溶液还含有稳定剂以抑制眼用溶液中PGF2α类似物的分解。优选的稳定剂的实例为乙二胺四乙酸及其盐类,例如依地酸二钠和二丁基羟基甲苯。还可以使用其它稳定剂,例如亚硝酸钠、抗坏血酸、L-抗坏血酸硬脂酸酯、亚硫酸氢钠、α硫代甘油(alphathioglycerin)、异抗坏血酸、盐酸半胱氨酸、柠檬酸、醋酸生育酚、二氯异氰尿酸钾、2,6-二叔丁基-4-甲酚、大豆卵磷脂、巯基乙酸钠(sodium thioglycollate)、硫代苹果酸钠、天然维生素E、生育酚、ascorbyl pasthyminate、焦亚硫酸钠、丁基羟基茴香醚、1,3-丁二醇、季戊四醇(pentaerythtyl)四[3-(3,5-二叔丁基-4-羟苯基)]丙酸酯、没食子酸丙酯、2-巯基苯并咪唑和硫酸羟基喹啉。
可以根据具体的稳定剂选择本发明的眼用溶液中稳定剂的量,并且在本领域技术人员的能力内。例如,当稳定剂为依地酸二钠时,其浓度通常为0.005-0.2%(w/v),优选0.01-0.1%,甚至更优选约0.05%。
优选的用于本发明的眼用含水溶液中的PGF2α类似物为他氟前列素。然而,还可以使用所有已知的PGF2α类似物,尤其是其他ω链苯环取代的PGF2α类似物例如拉坦前列素、曲伏前列素和比马前列素或两种或多种***素的混合物。用于本发明的眼用含水溶液中的替代药物为其他的***素及其衍生物,例如***素E 及其类似物(参见US 6,344,477和其中的参考文献)。***素或类似物与其他眼科药物例如β-阻断剂如噻吗洛尔的组合也是合适的。
可以根据具体的上述***素、所治疗的疾病及其症状,选择本发明的眼用溶液中PGF2α类似物的量。对于他氟前列素,例如0.0001-0.01%,优选约0.0005-0.0025%,甚至更优选0.0010-0.0025%(w/v)的量被认为是充分的。其他PGF2α类似物用于治疗青光眼的优选浓度为曲伏前列素0.001-0.004%、拉坦前列素约0.005%、比马前列素约0.03%和乌诺前列酮约0.15%。
本发明的眼用溶液还可以包含用于眼用组合物中的常规辅料,例如缓冲剂、溶剂、pH 调节剂、张度剂(tonicity agent)等。合适的缓冲剂的实例包括但不限于磷酸二氢钠二水合物、硼酸、硼砂、柠檬酸或ε-氨基已酸。张度剂的具体实例包括但不限于甘油、山梨醇、甘露醇和其他糖醇、丙二醇、氯化钠、氯化钾和氯化钙。
本发明的眼用含水溶液的pH优选为4-8,更优选5-7。对于pH 调节剂,可以使用常规的pH 调节剂,例如氢氧化钠和/或盐酸。
树脂容器的材料基本上由聚乙烯组成。容器材料可以含有少量的除聚乙烯外的其他材料,例如聚丙烯、聚对苯二甲酸乙二醇酯、聚氯乙烯、丙烯酸树脂、聚苯乙烯、聚甲基丙烯酸甲酯和尼龙6。所述材料的量优选不超过总容器材料的约5-10%。聚乙烯根据其密度被分为多种类型,即低密度聚乙烯(LDPE)、中密度聚乙烯(MDPE)、高密度聚乙烯(HDPE)等,这些聚乙烯都包括在本发明中。优选的聚乙烯为LDPE。
用于包装和储存本发明的眼用含水溶液的容器包括所有适用于使用者友好地局部眼用递送的容器形式。因此,该容器可以选自例如单次单位剂量形式或多剂量形式的瓶、管、安瓿、吸量管和流体分配器。根据本发明优选的实施方案,眼用含水溶液为单剂量或单位剂量形式。
用于本发明的眼用溶液的容器优选通过挤出吹塑成型方法制造。与通常用于制造例如聚乙烯多剂量瓶的注射吹塑成型相比,挤出吹塑成型生成更平滑的容器内表面。与通过注射吹塑成型制造的聚乙烯容器相比,更平滑的内表面得到***素在聚乙烯容器中更好的化学稳定性。此外,当使用单剂量容器时,它们在成型过程中通过加热进行灭菌,不需要对容器另外灭菌,这也改善***素在单剂量容器中的稳定性 (参见EP 1 825 855和EP 1 349 580)。
通常,通过吹塑成型方法制造的单位剂量眼用容器的容积约1 ml,填充约0.2-0.5 ml的溶液。已知这类容器的形状种类繁多。典型的实例参见US 5,409,125和US 6,241,124。
虽然就本发明的目的而言单位剂量容器是优选的,但是本发明的眼用含水溶液在用于分配微量无菌流体的流体分配器中或任何其他眼用含水溶液与基本上由聚乙烯组成的容器材料接触的容器类型中,也保持溶解、稳定以及可生物利用。这类流体分配器公开于例如US 5,614,172中。
本发明的不含防腐剂的眼用含水溶液可以在室温下在包括单位剂量吸量管和分配器的上述合适的容器中储存。稳定性研究已经表明本发明的不含防腐剂的含水眼用他氟前列素溶液在聚乙烯容器中长期、在25℃下至少12个月以及在5℃下至少30个月内是稳定的。
优选的本发明的实施方案为用于治疗高眼压和青光眼的含水眼用溶液,其在基本上由聚乙烯组成的容器中包含:
0.0001 – 0.01%w/v PGF2α类似物;
0.05 – 0.5%w/v 非离子表面活性剂,
0.005 – 0.2%w/v 稳定剂,
基本上不含防腐剂,和
任选的眼用溶液中常规使用的缓冲剂、pH调节剂和张度剂。
下列实施例对本发明进行了说明,而不以任何方式限定本发明。
实施例 1
研究非离子表面活性剂在5℃、25℃和40℃下在20周内对不含防腐剂的他氟前列素被低密度聚乙烯容器吸收的作用。使用三种不同的聚山梨酯80 (吐温80) 浓度,即0.05%、0.075%和0.1%。除了聚山梨酯80外,不含防腐剂的含水他氟前列素制剂的组合物为0.0015%他氟前列素、2.25%甘油、0.2%磷酸二氢钠二水合物、0.05%依地酸二钠以及调节pH至5.0 – 6.7的氢氧化钠和/或盐酸。
将上述制备的0.3 ml 组合物填充到单位剂量容器(LDPE)的主体部分,通过加热容器(LDPE)的上部进行密封。单位剂量容器的内部容积为约1 ml。将容器包装在纸涂布的铝-聚乙烯箔中并且储存于冰箱或保温箱中。
通过HPLC测量他氟前列素的剩余浓度。结果显示于图1-3中。该结果表明聚山梨酯的浓度对他氟前列素被聚乙烯吸收具有影响。聚山梨酯(0.05-0.1%)抑制他氟前列素的吸收,尤其是在升高的温度(40℃)下。0.075-0.1%量的聚山梨酯对他氟前列素的吸收显示良好的抑制作用。
实施例 2
研究在单次滴注
1) 含有0.01%BAK和0.05%聚山梨酯80的防腐的0.0015%他氟前列素眼用溶液,或
2) 含有0.20%聚山梨酯80的非-防腐的0.0015%他氟前列素眼用溶液,或
3) 含有0.05%聚山梨酯80的非-防腐的0.0015%他氟前列素眼用溶液后家兔房水中他氟前列素游离酸的浓度。
除聚山梨酯80外,非-防腐的溶液中成分的浓度如下:2.25%甘油,0.2%磷酸二氢钠二水合物,0.05%依地酸二钠以及调节pH至5.0 – 6.7的氢氧化钠和/或盐酸。
家兔接受上述眼用溶液。在每个时间点处死家兔(每个时间点每种处理4只动物)并提取房水样本。使用验证的LC-MS/MS方法测量他氟前列素酸形式的浓度。
结果 (每个时间点每种测试溶液N= 8) 显示于图4中。
由结果可以看出,非离子表面活性剂的量对眼部生物利用度有影响。当非离子表面活性剂的量超过一定限度时,活性剂向房水的渗透开始降低。因此需要平衡非离子表面活性剂的量,一方面最小化PGF2α类似物被容器壁吸收,另一方面,最大化眼部生物利用度。
Claims (30)
1.一种用于治疗高眼压和青光眼的滴眼水性溶液制品,其仅由滴眼水性溶液和基本上由聚乙烯组成的容器构成,所述滴眼水性溶液包含PGF2α类似物作为有效成分,另外,含有非离子表面活性剂、稳定剂,并且基本上不含防腐剂,其中非离子表面活性剂的量为0.05-0.5%w/v,
所述PGF2α类似物选自拉坦前列素、异丙基乌诺前列酮、曲伏前列素、比马前列素和他氟前列素或其两种以上的混合物,
基本上由聚乙烯组成的容器是指仅由聚乙烯组成的容器,或者由聚乙烯和相对于全部容器材料5-10%的其他材料组成的容器,
基本上不含防腐剂是指溶液完全不含有防腐剂,或者溶液含有检测不到的浓度的防腐剂或者不提供防腐效果浓度的防腐剂。
2.根据权利要求1的滴眼水性溶液制品,其中所述非离子表面活性剂的量为0.05-0.1%w/v。
3.根据权利要求1的滴眼水性溶液制品,其中所述非离子表面活性剂的量为0.075%w/v。
4.根据权利要求1的滴眼水性溶液制品,其中PGF2α类似物为他氟前列素。
5.根据权利要求1-4任一所述的滴眼水性溶液制品,所述其他材料为聚丙烯、聚对苯二甲酸乙二醇酯、聚氯乙烯、丙烯酸树脂、聚苯乙烯、聚甲基丙烯酸甲酯或尼龙6。
6.根据权利要求1所述的滴眼水性溶液制品,其中非离子表面活性剂选自聚氧乙烯脂肪酸酯,聚氧乙烯氢化蓖麻油类,聚氧乙烯聚氧丙烯二醇类,聚乙二醇40硬脂酸酯和蔗糖脂肪酸酯。
7.根据权利要求6所述的滴眼水性溶液制品,其中所述聚氧乙烯脂肪酸酯选自聚山梨酯80[聚(氧乙烯)脱水山梨糖醇单油酸酯]、聚山梨酯60[聚(氧乙烯)脱水山梨糖醇单硬脂酸酯]、聚山梨酯40[聚(氧乙烯)脱水山梨糖醇单棕榈酸酯]、聚(氧乙烯)脱水山梨糖醇单月桂酸酯、聚(氧乙烯)脱水山梨糖醇三油酸酯和聚山梨酯65[聚(氧乙烯)脱水山梨糖醇三硬脂酸酯]。
8.根据权利要求6所述的滴眼水性溶液制品,其中聚氧乙烯氢化蓖麻油类选自聚氧乙烯氢化蓖麻油 10、聚氧乙烯氢化蓖麻油 40、聚氧乙烯氢化蓖麻油 50和聚氧乙烯氢化蓖麻油60。
9. 根据权利要求6所述的滴眼水性溶液制品,其中聚氧乙烯聚氧丙烯二醇类选自聚氧乙烯(160)聚氧丙烯(30)二醇[普朗尼克F68]、聚氧乙烯(42)聚氧丙烯(67)二醇[普朗尼克P123]、聚氧乙烯(54)聚氧丙烯(39)二醇[普朗尼克P85]、聚氧乙烯(196)聚氧丙烯(67)二醇[普朗尼克F127]和聚氧乙烯(20)聚氧丙烯(20)二醇[普朗尼克L-44]。
10.根据权利要求6所述的滴眼水性溶液制品,其中非离子表面活性剂为聚山梨酯80或聚氧乙烯氢化蓖麻油类。
11.根据权利要求1所述的滴眼水性溶液制品,其中稳定剂选自乙二胺四乙酸及其盐类、亚硝酸钠、抗坏血酸、L-抗坏血酸硬脂酸酯、亚硫酸氢钠、α硫代甘油、异抗坏血酸、盐酸半胱氨酸、柠檬酸、醋酸生育酚、二氯异氰尿酸钾、2,6-二叔丁基-4-甲酚、大豆卵磷脂、巯基乙酸钠、硫代苹果酸钠、天然维生素E、焦亚硫酸钠、丁基羟基茴香醚、1,3-丁二醇、季戊四醇四[3-(3,5-二叔丁基-4-羟苯基)]丙酸酯、没食子酸丙酯、2-巯基苯并咪唑和硫酸羟基喹啉。
12.根据权利要求11的滴眼水性溶液制品,其中稳定剂为依地酸二钠。
13.根据权利要求1所述的滴眼水性溶液制品,其中稳定剂的量为0.005-0.2% w/v。
14.根据权利要求1所述的滴眼水性溶液制品,其中稳定剂的量为0.01-0.1% w/v。
15.根据权利要求1所述的滴眼水性溶液制品,其中稳定剂的量为0.05%w/v。
16.根据权利要求1的滴眼水性溶液制品,其为单剂量形式。
17.根据权利要求1所述的滴眼水性溶液制品,包含至少一种其它药学活性物质。
18.根据权利要求17所述的滴眼水性溶液制品,所述其它药学活性物质为噻吗洛尔。
19.一种滴眼水性溶液制品,其仅由滴眼水性溶液和基本上由聚乙烯组成的容器构成,
所述滴眼水性溶液包含:
0.0001 – 0.01%w/v PGF2α类似物;
0.05 – 0.5%w/v 非离子表面活性剂,
0.005 – 0.2%w/v 稳定剂,和
任选的眼用溶液中常规使用的缓冲剂、pH调节剂和张度剂,并且基本上不含防腐剂,
所述滴眼水性溶液在基本上由聚乙烯组成的容器中或与基本上由聚乙烯组成的容器材料接触,
所述PGF2α类似物选自拉坦前列素、异丙基乌诺前列酮、曲伏前列素、比马前列素和他氟前列素或其两种以上的混合物,
基本上由聚乙烯组成的容器是指仅由聚乙烯组成的容器,或者由聚乙烯和相对于全部容器材料5-10%的其他材料组成的容器,
基本上不含防腐剂是指溶液完全不含有防腐剂,或者溶液含有检测不到的浓度的防腐剂或者不提供防腐效果浓度的防腐剂。
20.一种滴眼水性溶液制品,其仅由滴眼水性溶液和基本上由聚乙烯组成的容器构成,
所述滴眼水性溶液包含:
0.0010 – 0.0015%w/v 他氟前列素;
0.05 – 0.1%w/v 聚山梨酯80,
0.01 – 0.1%w/v 依地酸二钠,和
任选的眼用溶液中常规使用的缓冲剂、pH调节剂和张度剂,并且基本上不含防腐剂,
所述滴眼水性溶液在基本上由聚乙烯组成的容器中或与基本上由聚乙烯组成的容器材料接触,
基本上由聚乙烯组成的容器是指仅由聚乙烯组成的容器,或者由聚乙烯和相对于全部容器材料5-10%的其他材料组成的容器,
基本上不含防腐剂是指溶液完全不含有防腐剂,或者溶液含有检测不到的浓度的防腐剂或者不提供防腐效果浓度的防腐剂。
21.一种滴眼水性溶液制品,其仅由滴眼水性溶液和基本上由聚乙烯组成的容器构成,
所述滴眼水性溶液包含:
0.0015%w/v 他氟前列素,
0.075%w/v 聚山梨酯80,
0.05%w/v 依地酸二钠,
2.25%w/v 甘油,
0.2%w/v 磷酸二氢钠二水合物,
pH调节剂,并且基本上不含防腐剂,
所述滴眼水性溶液在基本上由聚乙烯组成的容器中或与基本上由聚乙烯组成的容器材料接触,
基本上由聚乙烯组成的容器是指仅由聚乙烯组成的容器,或者由聚乙烯和相对于全部容器材料5-10%的其他材料组成的容器,
基本上不含防腐剂是指溶液完全不含有防腐剂,或者溶液含有检测不到的浓度的防腐剂或者不提供防腐效果浓度的防腐剂。
22.根据权利要求19-21任一所述的滴眼水性溶液制品,所述其他材料为聚丙烯、聚对苯二甲酸乙二醇酯、聚氯乙烯、丙烯酸树脂、聚苯乙烯、聚甲基丙烯酸甲酯或尼龙6。
23.根据权利要求19-21任一所述的滴眼水性溶液制品,其为单剂量或单位剂量形式。
24.根据权利要求19-21任一所述的滴眼水性溶液制品,其为流体分配器形式。
25.一种增加滴眼水性溶液中PGF2α类似物的水溶性和改善其稳定性的方法,包含制备含有PGF2α类似物、非离子表面活性剂、稳定剂并且基本上不含防腐剂的滴眼水性溶液的步骤,以及将上述不含防腐剂的眼用溶液包装于基本上由聚乙烯组成的容器中或与基本上由聚乙烯组成的容器材料接触的步骤,其中非离子表面活性剂的量为0.05-0.5%w/v,
所述PGF2α类似物选自拉坦前列素、异丙基乌诺前列酮、曲伏前列素、比马前列素和他氟前列素或其两种以上的混合物
基本上由聚乙烯组成的容器是指仅由聚乙烯组成的容器,或者由聚乙烯和相对于全部容器材料5-10%的其他材料组成的容器,
基本上不含防腐剂是指溶液完全不含有防腐剂,或者溶液含有检测不到的浓度的防腐剂或者不提供防腐效果浓度的防腐剂。
26.根据权利要求25的方法,其中非离子表面活性剂的量为0.05-0.1%w/v。
27.根据权利要求25的方法,其中非离子表面活性剂的量为0.075%w/v。
28.PGF2α类似物在制备用于治疗高眼压和青光眼的滴眼水性溶液制品中的用途,其中所述滴眼水性溶液包含非离子表面活性剂、稳定剂,并且基本上不含防腐剂,其中非离子表面活性剂的量为0.05-0.5%w/v,
所述滴眼水性溶液包装于基本上由聚乙烯组成的容器中或与基本上由聚乙烯组成的容器材料接触,
所述PGF2α类似物选自拉坦前列素、异丙基乌诺前列酮、曲伏前列素、比马前列素和他氟前列素或其两种以上的混合物,
基本上由聚乙烯组成的容器是指仅由聚乙烯组成的容器,或者由聚乙烯和相对于全部容器材料5-10%的其他材料组成的容器,
基本上不含防腐剂是指溶液完全不含有防腐剂,或者溶液含有检测不到的浓度的防腐剂或者不提供防腐效果浓度的防腐剂。
29.根据权利要求28的用途,其中非离子表面活性剂的量为0.05-0.1%w/v。
30.根据权利要求28的用途,其中非离子表面活性剂的量为0.075%w/v。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08397513A EP2127638A1 (en) | 2008-05-30 | 2008-05-30 | Method and composition for treating ocular hypertension and glaucoma |
EP08397513.6 | 2008-05-30 | ||
PCT/JP2009/060211 WO2009145356A1 (en) | 2008-05-30 | 2009-05-28 | Method and composition for treating ocular hypertension and glaucoma |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102083413A CN102083413A (zh) | 2011-06-01 |
CN102083413B true CN102083413B (zh) | 2013-11-06 |
Family
ID=39940592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801197245A Active CN102083413B (zh) | 2008-05-30 | 2009-05-28 | 用于治疗高眼压和青光眼的方法和组合物 |
Country Status (27)
Country | Link |
---|---|
US (3) | US9999593B2 (zh) |
EP (7) | EP2127638A1 (zh) |
JP (9) | JP2011521943A (zh) |
KR (5) | KR101650006B1 (zh) |
CN (1) | CN102083413B (zh) |
AR (2) | AR071937A1 (zh) |
AU (1) | AU2009252210C1 (zh) |
BR (1) | BRPI0913109B8 (zh) |
CA (2) | CA2724194C (zh) |
CY (2) | CY1115565T1 (zh) |
DK (4) | DK2306977T3 (zh) |
EA (1) | EA023661B1 (zh) |
ES (5) | ES2808050T3 (zh) |
GE (1) | GEP20156220B (zh) |
HR (4) | HRP20220361T1 (zh) |
HU (3) | HUE033103T2 (zh) |
JO (1) | JO3039B1 (zh) |
LT (3) | LT2772249T (zh) |
MX (1) | MX2010012987A (zh) |
MY (1) | MY159463A (zh) |
PL (4) | PL2772249T3 (zh) |
PT (4) | PT3205334T (zh) |
SG (1) | SG191628A1 (zh) |
SI (4) | SI3714877T1 (zh) |
TW (1) | TWI432202B (zh) |
UA (1) | UA102257C2 (zh) |
WO (1) | WO2009145356A1 (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI544927B (zh) | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
EP2127638A1 (en) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
JP5681472B2 (ja) * | 2009-12-28 | 2015-03-11 | ロート製薬株式会社 | 眼科用組成物 |
FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
AU2011282681B2 (en) * | 2010-07-29 | 2015-07-30 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
EP2598117A2 (en) * | 2010-07-29 | 2013-06-05 | Allergan, Inc. | Preservative free bimatoprost solutions |
WO2012021107A2 (en) | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
EP2618810B1 (en) | 2010-09-21 | 2016-11-23 | S & V Technologies GmbH | Cosmetic composition |
EP2452669A1 (en) * | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
WO2012141334A1 (en) * | 2011-04-12 | 2012-10-18 | R-Tech Ueno, Ltd. | Aqueous ophthalmic composition |
CN102716074B (zh) * | 2012-06-28 | 2013-10-16 | 武汉武药科技有限公司 | 一种贝美前列素滴眼剂及其制备方法 |
FI2887923T3 (fi) * | 2012-08-24 | 2023-06-30 | Sun Pharmaceutical Ind Ltd | Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
US9913849B2 (en) | 2014-01-10 | 2018-03-13 | Manistee Partners Llc | Treatment of migraines |
CN104766952B (zh) * | 2015-04-21 | 2017-01-25 | 武汉凯迪工程技术研究总院有限公司 | 利用生物质气化炉滤渣制备锂离子电池负极材料的方法 |
EP3103439B1 (en) | 2015-06-09 | 2019-08-07 | MEDproject Pharma-Entwicklungs- und Vertriebsgesellschaft mbH | Drippable ophthalmic bimatoprost gel |
US10105371B2 (en) * | 2015-10-09 | 2018-10-23 | Tamara Vrabec | Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject |
CA3004587A1 (en) * | 2015-11-06 | 2017-05-11 | Accuitis Pharmaceuticals, Inc. | Use of proteasome inhibitors to treat ocular disorders |
BR112018067946A8 (pt) | 2016-02-29 | 2022-11-08 | Sun Pharma Global Fze | Formulações tópicas contendo ciclosporina e usos das mesmas |
GR1009040B (el) | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
WO2018033854A1 (en) * | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
KR101770324B1 (ko) * | 2016-11-09 | 2017-08-22 | 주식회사태준제약 | 안압 강하용 점안 조성물 |
JP2020059652A (ja) * | 2016-12-26 | 2020-04-16 | 参天製薬株式会社 | タフルプロストとクエン酸エステルとを含有するデポ剤 |
ES2972844T3 (es) * | 2017-03-27 | 2024-06-17 | Alcon Inc | Preparación farmacéutica |
US20180318319A1 (en) * | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
EP3643297A4 (en) | 2017-06-22 | 2021-03-17 | Yonsung Fine Chemical Co., Ltd. | OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT |
CN111479568A (zh) * | 2017-12-21 | 2020-07-31 | 参天制药株式会社 | 司培前列素与Rho激酶抑制剂的组合药物 |
WO2020013717A1 (en) | 2018-07-09 | 2020-01-16 | Warszawskie Zaklady Farmaceutyczne Polfa Sa | Ophthalmic dispensing device |
CN111632025A (zh) * | 2020-03-04 | 2020-09-08 | 吉林大学第一医院 | 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用 |
CN111840225B (zh) * | 2020-08-12 | 2021-09-14 | 陈丽娜 | 一种用于治疗青光眼的滴眼剂及其制备方法 |
RU2761625C2 (ru) * | 2021-02-11 | 2021-12-13 | Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") | Фармацевтическая композиция тафлупроста |
WO2023182480A1 (ja) * | 2022-03-25 | 2023-09-28 | 株式会社坪田ラボ | 水性組成物 |
WO2023241652A1 (zh) * | 2022-06-16 | 2023-12-21 | 广州润尔眼科生物科技有限公司 | 一种药物组合物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1321144A1 (en) * | 2000-09-13 | 2003-06-25 | Santen Pharmaceutical Co., Ltd. | Eye drops |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778815A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one |
EP0286903B2 (en) | 1987-04-03 | 2000-03-29 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
DE4027320C2 (de) | 1990-08-29 | 1993-09-30 | Ursapharm Arzneimittel Gmbh | Fluid-Abgabeeinrichtung für keimfreies Fluid |
JPH0655640A (ja) | 1992-08-04 | 1994-03-01 | Aavan Internatl:Kk | 洗面台カウンター及びその製造方法 |
JPH06107547A (ja) | 1992-10-01 | 1994-04-19 | Aarutetsuku Ueno:Kk | 眼科用組成物 |
AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
JP2510066Y2 (ja) | 1993-01-20 | 1996-09-11 | 東洋製罐株式会社 | 加熱殺菌可能な液体医薬容器 |
US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
AU704938B2 (en) * | 1995-11-17 | 1999-05-06 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
DE69714274T3 (de) | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
WO1998025829A1 (en) | 1996-12-09 | 1998-06-18 | Bausch & Lomb Incorporated | Single-use flexible container |
JP3480549B2 (ja) | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | ジフルオロプロスタグランジン誘導体およびその用途 |
AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
EP0979652B1 (en) | 1997-10-13 | 2006-05-24 | R-Tech Ueno, Ltd. | Remedial composition for intraocular hypertension or glaucoma |
US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
GB2337740B (en) | 1998-05-26 | 2000-11-15 | Spreckelsen Mcgeough Ltd | Fluid packaging |
WO2000003736A1 (en) | 1998-07-14 | 2000-01-27 | Alcon Laboratories, Inc. | Prostaglandin product |
US6235781B1 (en) | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
JP2003517441A (ja) | 1998-09-25 | 2003-05-27 | アルコン ラボラトリーズ, インコーポレイテッド | 徐放性で快適な眼疾病用組成物および眼疾病の治療方法 |
US6096783A (en) | 1998-12-15 | 2000-08-01 | Alcon Laboratories, Inc. | Cyclobutane prostaglandin analogues as ocular hypotensive agents |
AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
PL350924A1 (en) | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
AU2001264261A1 (en) | 2000-06-19 | 2002-01-02 | Santen Pharmaceutical Co. Ltd. | Aseptics |
JP3876355B2 (ja) * | 2000-09-13 | 2007-01-31 | 参天製薬株式会社 | 点眼液 |
TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
AU2003248070A1 (en) | 2002-07-16 | 2004-02-02 | Hanshin Yoki Co., Ltd. | Chemical container and method of manufacturing the container |
KR101253941B1 (ko) | 2002-09-09 | 2013-04-16 | 산텐 세이야꾸 가부시키가이샤 | 라타노프로스트를 유효 성분으로 하는 투명한 점안액 |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
EP1666043B1 (en) | 2003-07-31 | 2009-12-02 | Santen Pharmaceutical Co., Ltd. | Product containing prostaglandin |
US20050287325A1 (en) | 2004-06-25 | 2005-12-29 | Pharmacia & Upjohn Company | Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients |
ATE412400T1 (de) | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
WO2007042262A2 (en) | 2005-10-10 | 2007-04-19 | Novagali Pharma Sa | Ophthalmic emulsions containing prostaglandins |
WO2006058139A2 (en) | 2004-11-24 | 2006-06-01 | Holopack International Corp. | Dispensing container with flow control system |
CN102526064A (zh) * | 2004-12-09 | 2012-07-04 | 参天制药株式会社 | 含有分子内具有氟原子的***素的制品 |
DK1829545T3 (da) | 2004-12-24 | 2012-07-23 | Santen Pharmaceutical Co Ltd | Produkter indeholdende prostaglandin-F2alfa-derivat |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
WO2007007832A1 (ja) | 2005-07-13 | 2007-01-18 | Santen Pharmaceutical Co., Ltd. | 眼科用防腐組成物 |
US8030349B2 (en) | 2005-08-02 | 2011-10-04 | Santen Pharmaceutical Co., Ltd. | Method for prevention of degradation of thermally unstable medicament |
FI126233B (sv) | 2006-02-23 | 2016-08-31 | Oy Kwh Mirka Ab | Oscillerande slipmaskin |
FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
KR100927617B1 (ko) | 2007-11-26 | 2009-11-23 | 한국표준과학연구원 | 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법 |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
-
2008
- 2008-05-30 EP EP08397513A patent/EP2127638A1/en not_active Withdrawn
-
2009
- 2009-05-19 TW TW098116503A patent/TWI432202B/zh active
- 2009-05-27 JO JOP/2009/0192A patent/JO3039B1/ar active
- 2009-05-28 SG SG2013041751A patent/SG191628A1/en unknown
- 2009-05-28 PL PL14001862T patent/PL2772249T3/pl unknown
- 2009-05-28 PL PL20164602T patent/PL3714877T3/pl unknown
- 2009-05-28 PT PT170004402T patent/PT3205334T/pt unknown
- 2009-05-28 UA UAA201015619A patent/UA102257C2/uk unknown
- 2009-05-28 MY MYPI2010005463A patent/MY159463A/en unknown
- 2009-05-28 SI SI200932159T patent/SI3714877T1/sl unknown
- 2009-05-28 ES ES17000440T patent/ES2808050T3/es active Active
- 2009-05-28 PL PL17000440T patent/PL3205334T3/pl unknown
- 2009-05-28 HU HUE14001862A patent/HUE033103T2/en unknown
- 2009-05-28 EP EP14001862.3A patent/EP2772249B1/en not_active Revoked
- 2009-05-28 HU HUE17000440A patent/HUE049923T2/hu unknown
- 2009-05-28 AR ARP090101912A patent/AR071937A1/es not_active Application Discontinuation
- 2009-05-28 HR HRP20220361TT patent/HRP20220361T1/hr unknown
- 2009-05-28 EP EP17000440.2A patent/EP3205334B1/en active Active
- 2009-05-28 SI SI200932073T patent/SI3205334T1/sl unknown
- 2009-05-28 ES ES20164602T patent/ES2907982T3/es active Active
- 2009-05-28 KR KR1020107029072A patent/KR101650006B1/ko active IP Right Grant
- 2009-05-28 EA EA201071413A patent/EA023661B1/ru unknown
- 2009-05-28 AU AU2009252210A patent/AU2009252210C1/en active Active
- 2009-05-28 EP EP21217057.5A patent/EP4035656B1/en active Active
- 2009-05-28 PL PL09754864T patent/PL2306977T3/pl unknown
- 2009-05-28 LT LTEP14001862.3T patent/LT2772249T/lt unknown
- 2009-05-28 ES ES14001862.3T patent/ES2627837T3/es active Active
- 2009-05-28 CA CA2724194A patent/CA2724194C/en active Active
- 2009-05-28 JP JP2011511256A patent/JP2011521943A/ja active Pending
- 2009-05-28 KR KR1020197016340A patent/KR102114401B1/ko active IP Right Grant
- 2009-05-28 LT LTEP17000440.2T patent/LT3205334T/lt unknown
- 2009-05-28 EP EP20164602.3A patent/EP3714877B1/en active Active
- 2009-05-28 SI SI200931050T patent/SI2306977T1/sl unknown
- 2009-05-28 DK DK09754864.8T patent/DK2306977T3/da active
- 2009-05-28 ES ES09754864.8T patent/ES2495316T3/es active Active
- 2009-05-28 DK DK20164602.3T patent/DK3714877T3/da active
- 2009-05-28 LT LTEP20164602.3T patent/LT3714877T/lt unknown
- 2009-05-28 PT PT140018623T patent/PT2772249T/pt unknown
- 2009-05-28 ES ES21217057T patent/ES2968837T3/es active Active
- 2009-05-28 SI SI200931694T patent/SI2772249T1/sl unknown
- 2009-05-28 EP EP09754864.8A patent/EP2306977B1/en active Active
- 2009-05-28 KR KR1020187001130A patent/KR101988642B1/ko active IP Right Grant
- 2009-05-28 BR BRPI0913109A patent/BRPI0913109B8/pt active IP Right Grant
- 2009-05-28 EP EP23202597.3A patent/EP4289446A3/en active Pending
- 2009-05-28 DK DK14001862.3T patent/DK2772249T3/en active
- 2009-05-28 CN CN2009801197245A patent/CN102083413B/zh active Active
- 2009-05-28 PT PT97548648T patent/PT2306977E/pt unknown
- 2009-05-28 GE GEAP200912045A patent/GEP20156220B/en unknown
- 2009-05-28 KR KR1020167022210A patent/KR101820816B1/ko active IP Right Grant
- 2009-05-28 DK DK17000440.2T patent/DK3205334T3/da active
- 2009-05-28 PT PT201646023T patent/PT3714877T/pt unknown
- 2009-05-28 MX MX2010012987A patent/MX2010012987A/es active IP Right Grant
- 2009-05-28 HU HUE20164602A patent/HUE058079T2/hu unknown
- 2009-05-28 WO PCT/JP2009/060211 patent/WO2009145356A1/en active Application Filing
- 2009-05-28 US US12/995,351 patent/US9999593B2/en active Active
- 2009-05-28 CA CA2965185A patent/CA2965185A1/en not_active Abandoned
- 2009-05-28 KR KR1020207014211A patent/KR102246598B1/ko active IP Right Grant
-
2014
- 2014-04-22 JP JP2014088256A patent/JP2014133765A/ja active Pending
- 2014-09-18 CY CY20141100763T patent/CY1115565T1/el unknown
- 2014-10-14 HR HRP20140979AT patent/HRP20140979T1/hr unknown
-
2015
- 2015-12-07 JP JP2015238594A patent/JP6148317B2/ja active Active
-
2017
- 2017-05-18 JP JP2017098843A patent/JP6356868B2/ja active Active
- 2017-05-23 HR HRP20170769TT patent/HRP20170769T1/hr unknown
- 2017-06-27 CY CY20171100675T patent/CY1120351T1/el unknown
-
2018
- 2018-06-14 JP JP2018113647A patent/JP6649992B2/ja active Active
- 2018-06-18 US US16/010,739 patent/US10864159B2/en active Active
- 2018-11-01 AR ARP180103181A patent/AR120961A2/es not_active Application Discontinuation
-
2020
- 2020-01-17 JP JP2020005799A patent/JP6889789B2/ja active Active
- 2020-06-24 HR HRP20200998TT patent/HRP20200998T1/hr unknown
- 2020-11-11 US US17/094,986 patent/US20210059931A1/en not_active Abandoned
-
2021
- 2021-05-21 JP JP2021085839A patent/JP7265584B2/ja active Active
-
2023
- 2023-04-14 JP JP2023066348A patent/JP7520285B2/ja active Active
-
2024
- 2024-04-12 JP JP2024064531A patent/JP2024079852A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1321144A1 (en) * | 2000-09-13 | 2003-06-25 | Santen Pharmaceutical Co., Ltd. | Eye drops |
Non-Patent Citations (1)
Title |
---|
Emmanuelle Brasnu,et al.In vitro effects of preservative-free tafluprost and preserved latanoprost,travoprost,and bimatoprost in a conjunctival epithelial cell line.《Current eye research》.2008,第33卷(第4期),303-312. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102083413B (zh) | 用于治疗高眼压和青光眼的方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Osaka City, Osaka of Japan Co-patentee after: AGC Corporation Patentee after: Santen Pharmaceutical Co., Ltd. Address before: Osaka City, Osaka of Japan Co-patentee before: Asahi Glass Co., Ltd. Patentee before: Santen Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |